Arabic Arabic English English French French German German
dark

Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone

Xenon Pharmaceuticals Inc. today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieved a regulatory milestone, which has triggered an aggregate payment of $15.0 million to Xenon. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

40% of eligible population have had boosters; 28 community cases; 2 deaths; 31 people in hospital; two in ICU

Next Post

The unexpected benefits of fat in type 2 diabetes

Related Posts
Total
0
Share